Dynavax Technologies (NASDAQ:DVAX - Get Free Report) had its price target increased by HC Wainwright from $29.00 to $31.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 148.40% from the stock's previous close.
Dynavax Technologies Stock Performance
NASDAQ DVAX remained flat at $12.48 during trading on Tuesday. The company's stock had a trading volume of 1,464,350 shares, compared to its average volume of 2,092,156. The business's 50 day simple moving average is $12.76 and its two-hundred day simple moving average is $11.65. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies has a one year low of $9.74 and a one year high of $14.41. The company has a market cap of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34.
Institutional Trading of Dynavax Technologies
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DVAX. GAMMA Investing LLC boosted its stake in Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 1,685 shares in the last quarter. US Bancorp DE boosted its stake in shares of Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in Dynavax Technologies in the third quarter valued at about $45,000. Nisa Investment Advisors LLC grew its holdings in Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Dynavax Technologies in the 3rd quarter valued at $89,000. Institutional investors and hedge funds own 96.96% of the company's stock.
About Dynavax Technologies
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
